The tight bottleneck during HIV-1 transmission generally results in only a single virus variant being transmitted. Investigation of the HIV-1 envelope glycoprotein (Env) can identify vulnerabilities of transmitting viruses that can be targeted by vaccines designed to elicit protection against global HIV-1. This study generated an HIV-1 subtype C consensus transmitted and early founder virus Env (EnvFVC) after detailed sequence analysis of 1,894 env genes obtained from 80 acutely infected individuals from South Africa, Malawi, and Zambia. The inferred EnvFVC sequence incorporates characteristics of transmitted and early founder viruses and results in the expression of a functional and conformationally intact Env. Overall, the “subtype-based” or “region-based” EnvFVC described here can be used in the development of a useful immunogen for novel vaccine design.
Get full access to this article
View all access options for this article.
References
1.
AbrahamsMR, AndersonJA, GiorgiEE, SeoigheC, MlisanaK, PingLH, et al.: Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol, 2009; 83:3556–3567.
2.
ChohanB, LangD, SagarM, KorberB, LavreysL, RichardsonB, and OverbaughJ: Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol, 2005; 79:6528–6531.
3.
DerdeynCA, DeckerJM, Bibollet-RucheF, MokiliJL, MuldoonM, DenhamSA, et al.: Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science, 2004; 303:2019–2022.
4.
HaalandRE, HawkinsPA, Salazar-GonzalezJ, JohnsonA, TichacekA, KaritaE, et al.: Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog, 2009; 5:e1000274.
5.
KeeleBF, GiorgiEE, Salazar-GonzalezJF, DeckerJM, PhamKT, SalazarMG, et al.: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA, 2008; 105:7552–7557.
6.
Salazar-GonzalezJF, BailesE, PhamKT, SalazarMG, GuffeyMB, KeeleBF, et al.: Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol, 2008; 82:3952–3970.
7.
VarelaM, LandskronL, LaiRP, McKinleyTJ, BogersWM, VerschoorEJ, et al.: Molecular evolution analysis of the human immunodeficiency virus type 1 envelope in simian/human immunodeficiency virus-infected macaques: Implications for challenge dose selection. J Virol, 2011; 85:10332–10345.
8.
WeiX, DeckerJM, WangS, HuiH, KappesJC, WuX, et al.: Antibody neutralization and escape by HIV-1. Nature, 2003; 422:307–312.
9.
CicalaC, MartinelliE, McNallyJP, GoodeDL, GopaulR, HiattJ, et al.: The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA, 2009; 106:20877–20882.
10.
NawazF, CicalaC, Van RykD, BlockKE, JelicicK, McNallyJP, et al.: The genotype of early-transmitting HIV gp120s promotes α (4) β(7)-reactivity, revealing α (4) β(7)+/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog, 2011; 7:e1001301.
11.
ArienKK, AbrahaA, Quinones-MateuME, KestensL, VanhamG, and ArtsEJ: The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol, 2005; 79:8979–8990.
12.
ScheidJF, MouquetH, UeberheideB, DiskinR, KleinF, OliveiraTYK, et al.: Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science, 2011; 333:1633–1637.
13.
ZhouT, GeorgievI, WuX, YangZY, DaiK, FinziAS, et al.: Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 2010; 329:811–817.
14.
WuX, YangZY, LiY, HogerkorpCM, SchiefWR, SeamanMS, et al.: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010; 329:856–861.
15.
WuX, ZhouT, ZhuJ, ZhangB, GeorgievI, WangC, et al.:Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science, 2011; 333:1593–1602.
16.
WalkerLM, PhogatSK, Chan-HuiPY, WagnerD, PhungP, GossJL, et al.:Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science, 2009; 326:285–289.
17.
BonsignoriM, HwangKK, ChenX, TsaoCY, MorrisL, GrayE, et al.: Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol, 2011; 85:9998–10009.
18.
WalkerLM, HuberM, DooresKJ, FalkowskaE, PejchalR, JulienJ-P, et al.: Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature., 2011; 477:466–470.
19.
ConnorRI, SheridanKE, CeradiniD, ChoeS, and LandauNR: Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med, 1997; 184:621–628.
20.
DerdeynCA, DeckerJM, SfakianosJN, ZhangZ, O'BrienWA, RatnerL, et al.: Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol, 2001; 75:8605–8614.
21.
GaoF, WeaverEA, LuZ, LiY, LiaoHX, MaB, et al.: Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol, 2005; 79:1154–1163.
22.
KotheDL, DeckerJM, LiY, WengZ, Bibollet-RucheF, ZammitKP, et al.: Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology, 2007; 360:218–234.
23.
KotheDL, LiY, DeckerJM, Bibollet-RucheF, ZammitKP, SalazarMG, et al.: Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology, 2006; 352:438–449.
